MIRA Pharmaceuticals, Inc. (MIRA)
| Market Cap | 40.47M +113.3% |
| Revenue (ttm) | n/a |
| Net Income | -31.37M |
| EPS | -1.04 |
| Shares Out | 42.02M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 165,452 |
| Open | 0.9630 |
| Previous Close | 0.9751 |
| Day's Range | 0.9244 - 0.9630 |
| 52-Week Range | 0.9000 - 2.4500 |
| Beta | 1.50 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 14, 2026 |
About MIRA
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dem... [Read more]
Financial Performance
Financial StatementsNews
Mira announces results from Phase 1 trial evaluating Ketamir-2
MIRA Pharmaceuticals (MIRA) announced positive unblinded results from its completed Phase 1 clinical trial evaluating Ketamir-2, the Company’s proprietary selective oral NMDA receptor modulator. The r...
MIRA Pharmaceuticals Reports Positive Unblinded Phase 1 Data for Ketamir-2
Selective oral NMDA receptor modulator demonstrated favorable safety, tolerability, and pharmacokinetic profile supporting planned Phase 2a development in chemotherapy-induced peripheral neuropathy MI...
Mira announces acceptance of peer-reviewed SKNY-1 manuscript
Mira Pharmaceuticals (MIRA) announced the acceptance and publication of a peer-reviewed manuscript describing the preclinical pharmacology and activity of SKNY-1, the Company’s oral investigational dr...
MIRA Pharmaceuticals Announces Acceptance of Peer-Reviewed SKNY-1 Manuscript Highlighting Oral Obesity and Nicotine Addiction Drug Candidate
Peer-reviewed publication highlights preclinical findings demonstrating weight loss, lipid normalization, and reduction of compulsive feeding and nicotine-seeking behaviors MIAMI, FL / ACCESS Newswire...
Mira reports Mira-55 shows no THC-, Rimonabant-associated CNS side effects
MIRA Pharmaceuticals (MIRA) announced new preclinical data demonstrating that Mira-55 did not produce cannabinoid-like central nervous system side effects across a comprehensive battery of validated b...
MIRA Pharmaceuticals Reports Mira-55 Shows No THC- or Rimonabant-Associated CNS Side Effects in Preclinical Studies
Previously shown to deliver morphine-comparable pain relief without opioid-related risks in a validated inflammatory pain model, supporting planned IND submission for inflammatory pain MIAMI, FL / ACC...
Mira Pharmaceuticals completes Phase 1 dosing of Ketamir-2
MIRA Pharmaceuticals (MIRA) announced completion of dosing in its Phase 1 clinical trial evaluating Ketamir-2, the Company’s proprietary selective oral NMDA receptor modulator. The randomized, double-...
MIRA Pharmaceuticals Completes Phase 1 Dosing of Ketamir-2
Advancing a selective oral NMDA receptor modulator toward Phase 2a in chemotherapy-induced peripheral neuropathy following favorable Phase 1 safety and tolerability findings MIAMI, FLORIDA / ACCESS Ne...
Mira Pharmaceuticals initiates final cohort of Ketamir-2 Phase 1 study
MIRA Pharmaceuticals (MIRA) initiated dosing in the final cohort of its Phase 1 multiple ascending dose clinical trial evaluating Ketamir-2, its lead oral NMDA receptor antagonist. To date, 50 healthy...
MIRA Pharmaceuticals Initiates Final Cohort of Ketamir-2 Phase 1 Clinical Study as Company Prepares for Phase 2a Study
Company to Participate in BIO Partnering Summit and Present Phase 1 Ketamir-2 Data at American Association for Cancer Research (AACR)Annual Meeting MIAMI, FLORIDA / ACCESS Newswire / February 3, 2026 ...
Mira Pharmaceuticals initiated with a Buy at Rodman & Renshaw
Rodman & Renshaw analyst Mike King initiated coverage of Mira Pharmaceuticals (MIRA) with a Buy rating and $8 price target
Mira Pharmaceuticals initiates MAD Phase 1 study of oral ketamir-2
MIRA Pharmaceuticals (MIRA) announced the initiation of the multiple ascending dose portion of its ongoing Phase 1 clinical trial evaluating its lead oral candidate, Ketamir-2, in healthy volunteers. ...
MIRA Pharmaceuticals Initiates Multiple Ascending Dose (MAD) Phase 1 Study of Oral Ketamir-2 and Selects Chemotherapy-Induced Neuropathic Pain as Lead Phase 2a Indication
Advancing toward Phase 2a clinical evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track consideration MIAMI, FLORIDA / ACCESS Newswire / Oc...
Mira Pharmaceuticals announces preclinical data on oral Mira-55
MIRA Pharmaceuticals (MIRA) announced new preclinical data showing that oral Mira-55 normalized pain and significantly reduced inflammation, outperforming injected morphine in an established animal mo...
MIRA Pharmaceuticals Announces Oral Mira-55 Outperformed Injected Morphine in Normalizing Pain and Reducing Inflammation, Supporting Its Planned IND for Chronic Inflammatory Pain
Findings show oral Mira-55 fully normalized pain and significantly reduced inflammation, supporting IND plans and reinforcing MIRA's position in a $70 billion non-opioid pain market. MIAMI, FLORIDA / ...
Mira Pharmaceuticals closes acquisition of SKNY Pharmaceuticals
MIRA Pharmaceuticals (MIRA) has completed its acquisition of SKNY Pharmaceuticals,. As part of the transaction, SKNY fulfilled all closing obligations, contributing $5M in marketable securities to MIR...
MIRA Pharmaceuticals Closes Acquisition of SKNY Pharmaceuticals, Expands Pipeline with SKNY-1 for Obesity and Nicotine Addiction
Closing adds $5 million in marketable securities, strengthens financial position, and complements MIRA's advancing programs including Ketamir-2 and MIRA-55 MIAMI, FLORIDA / ACCESS Newswire / September...
Mira Pharmaceuticals announces topline results from Phase 1 SAD study
MIRA Pharmaceuticals (MIRA) announced topline results from the single ascending dose portion of its ongoing Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics of its lead...
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
Study demonstrated Ketamir-2 was safe and well tolerated at all dose levels, with a favorable safety and tolerability profile, with no severe or clinically significant adverse effects observed. The dr...
Mira Pharmaceuticals reports Ketamir-2 data in PTSD
MIRA Pharmaceuticals (MIRA) announced results demonstrating that its oral drug candidate Ketamir-2 restored normalized behavior in stressed animals within a validated model of post-traumatic stress di...
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA / ACCESS Newswire / September 16, 2025 / MIRA Pharma...
Mira Pharmaceuticals shareholders approve acquisition of SKNY Pharmaceuticals
MIRA Pharmaceuticals (MIRA) announced that its stockholders have approved the acquisition of SKNY Pharmaceuticals at the Company’s 2025 Annual Meeting of Stockholders. All proposals at the meeting wer...
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
SKNY transaction strengthens MIRA pipeline with SKNY-1, a differentiated oral candidate that has demonstrated up to 30% weight loss and nicotine craving reversal in preclinical studies. MIAMI, FL / AC...
Mira Pharmaceuticals completes Phase 1 SAD portion for oral Ketamir-2
MIRA Pharmaceuticals (MIRA) announced the completion of the Single Ascending Dose portion of its ongoing Phase 1 clinical trial evaluating oral Ketamir-2. The study, conducted at the Hadassah Clinical...
MIRA Pharmaceuticals Announces Completion of Phase 1 Single Ascending Dose for Oral Ketamir-2 with No Safety Concerns, Advances to Multiple Ascending Dose Stage
Following FDA IND clearance for neuropathic pain, the Company is preparing to initiate its U.S. Phase 2a trial in Q4 2025 MIAMI, FL / ACCESS Newswire / August 19, 2025 / MIRA Pharmaceuticals, Inc. (NA...